Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings or view top-rated stocks.

13 equities research analysts have issued 12 month price objectives for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $27.00 to $90.00. On average, they anticipate the company's stock price to reach $58.08 in the next year. This suggests a possible upside of 64.4% from the stock's current price.
View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts.

Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of 2023. Since then, ARWR shares have decreased by 12.9% and is now trading at $35.32.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ARWR earnings forecast.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its earnings results on Tuesday, May, 2nd. The biotechnology company reported $0.45 EPS for the quarter, topping the consensus estimate of ($0.65) by $1.10. The biotechnology company had revenue of $146.27 million for the quarter, compared to the consensus estimate of $45.48 million. Arrowhead Pharmaceuticals had a negative net margin of 53.83% and a negative trailing twelve-month return on equity of 33.49%. The company's revenue for the quarter was down 3.6% compared to the same quarter last year. During the same period last year, the firm earned $0.41 EPS.

ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Direxion mRNA ETF (MSGR), ALPS Medical Breakthroughs ETF (SBIO), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Biotech ETF (XBI), Neuberger Berman Disrupters ETF (NBDS), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.89%), State Street Corp (5.52%), JPMorgan Chase & Co. (2.72%), Geode Capital Management LLC (1.94%), Credit Suisse AG (1.30%) and FMR LLC (1.28%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Patrick O'brien and William D Waddill.
View institutional ownership trends.

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARWR stock can currently be purchased for approximately $35.32.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $3.78 billion and generates $243.23 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

The company employs 329 workers across the globe.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.